Cargando…

Editorial: The NAFLD-MAFLD conundrum

Detalles Bibliográficos
Autores principales:	Dalbeni, Andrea, Kumar, Rahul, Albhaisi, Somaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523378/ https://www.ncbi.nlm.nih.gov/pubmed/37772079 http://dx.doi.org/10.3389/fendo.2023.1267341

Ejemplares similares

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Current and Potential Therapies Targeting Inflammation in NASH
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults
por: Peng, Hongye, et al.
Publicado: (2023)

Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index–related parameters
por: Xue, Yan, et al.
Publicado: (2022)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation
por: Zhou, Ben‐Gang, et al.
Publicado: (2023)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

LPCN 1144 Resolves NAFLD in Hypogonadal Males
por: Albhaisi, Somaya, et al.
Publicado: (2020)

MAFLD and NAFLD in the prediction of incident chronic kidney disease
por: Kwon, So Yoon, et al.
Publicado: (2023)

The NAFLD–MAFLD debate through the lens of the Arab world
por: Tharwat, Mina, et al.
Publicado: (2022)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
por: Boccatonda, Andrea, et al.
Publicado: (2023)

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change
por: Singh, Shivaram P, et al.
Publicado: (2022)

Mining Gut Microbiota From Bariatric Surgery for MAFLD
por: Wu, Wei-Kai, et al.
Publicado: (2021)

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
por: Shepard, Christopher R.
Publicado: (2021)

Recent Developments in NAFLD
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
por: Abu-Farha, Mohamed, et al.
Publicado: (2022)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life
por: Attia, Dina, et al.
Publicado: (2022)

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
por: Lonardo, Amedeo
Publicado: (2021)

Treatments for NAFLD: State of Art
por: Mantovani, Alessandro, et al.
Publicado: (2021)

Editorial: Secreted proteins as novel biomarkers and therapeutic targets in NAFLD
por: Xiong, Xuelian
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Identifying advanced MAFLD in a cohort of T2DM and clinical features
por: Sanchez-Bao, Ana Maria, et al.
Publicado: (2023)

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
por: Musio, Alessandra, et al.
Publicado: (2023)

Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
por: Park, So Hee, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
por: Baratta, Francesco, et al.
Publicado: (2021)

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
por: Gatzios, Alexandra, et al.
Publicado: (2022)

Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
por: Luo, Kuanhong, et al.
Publicado: (2023)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations
por: Xu, Xin, et al.
Publicado: (2023)

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
por: Portincasa, Piero
Publicado: (2023)

Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States
por: Xie, Zhi-Qin, et al.
Publicado: (2022)

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
por: Chua, Damien, et al.
Publicado: (2022)

Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients
por: Ordoñez-Vázquez, Ana Luisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kif9344r8457d9a241iu72flco